The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Choosing between gene therapy and alloSCT for SCD
Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses considerations for selecting patients with sickle cell disease (SCD) for gene therapy or allogeneic stem cell transplantation (alloSCT). Key considerations include patient age and whether they have evidence of end-organ damage (EOD) or stroke. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: SOBI, Sanofi
Honoraria: Vertex
Research Funding: EDITAS
